Spermidine has been evaluated in at least 8 published human trials, with the SmartAge (Cell Reports 2021) and MemoriCog trials providing the strongest evidence for cognitive benefits. Additional trials are evaluating cardiovascular outcomes, immune function, gut health, and biological aging markers — with results expected between 2025 and 2027.

Are the SmartAge trial results reliable?

The SmartAge trial is double-blind, placebo-controlled, and published in a top-tier journal (Cell Reports, IF >8). The sample size (85 participants, 12 months) is adequate for the primary endpoint. Results have been independently replicated in MemoriCog. The evidence quality is strong.

Why hasn't spermidine been approved as a drug?

Spermidine is a naturally occurring compound in the human body and cannot be patented. This limits pharmaceutical investment in large clinical trials required for drug approval. It remains classified as a dietary supplement in most jurisdictions.